Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epirubicin and Rituximab in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma and CLL
NCT00062296Phase 2Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Mar 2003
- Primary completion
- Aug 2005
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epirubicin and rituximab in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL), sponsored by Fox Chase Cancer Center. Primary endpoint: Response Rate. Started Mar 2003; status: completed.
02
Drugs
epirubicinrituximab
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00062296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062296.